The European Commission has granted marketing approval for BioMarin’s 3,4-diaminopyridine (amifampridine phosphate), for the rare autoimmune disease Lambert Eaton Myasthenic Syndrome (LEMS). Reportedly, Amifampridine phosphate, developed by the
Keryx Biopharmaceuticals has reached an agreement with the FDA regarding a Special Protocol Assessment (SPA) on the design of a phase 3 clinical program for Zerenex (ferric citrate).
Luitpold Pharmaceuticals, a US subsidiary of Daiichi Sankyo, and PharmaForce have announced that PharmaForce has been acquired by Luitpold. The FTC cleared the transaction under the Hart-Scott-Rodino Antitrust
LifeVantage Corporation (LifeVantage) has received formal approval from the Mexican government to launch Protandim in Mexico. The company said that the initial shipments have cleared customs and Protandim
OncoGenex has received funding for a randomized, controlled, investigator-sponsored phase 2 clinical trial evaluating OGX-427, when administered as a monotherapy to patients with castrate resistant prostate cancer (CRPC).
Ensemble Discovery has announced the initiation of a strategic alliance with Pfizer, to discover and develop drug candidates of a novel class against a number of high-value pharmaceutical
Alnylam Pharmaceuticals has received a milestone payment from its partner Roche, related to initiation of pre-IND (investigational new drug application) studies for an RNAi therapeutics product candidate. Financial
Wockhardt has received tentative approval from the FDA for marketing the 5mg and 10mg tablets of Memantine HCI, which is used for treatment of moderate to severe Alzheimer’s
Pearl Therapeutics has announced positive results from a phase 2a dose-ranging study of PT001, the company’s glycopyrrolate hydrofluoroalkane metered dose inhaler (HFA-MDI) formulation. The data showed that PT001
Seaside Therapeutics has entered into a collaborative research agreement with Vanderbilt University Medical Center to discover and develop small molecules targeting neurologic receptors implicated in disorders of brain
Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.